Analyst Price Target is $9.31
▲ +1,127.43% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Cybin in the last 3 months. The average price target is $9.31, with a high forecast of $10.00 and a low forecast of $8.25. The average price target represents a 1,127.43% upside from the last price of $0.76.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Cybin.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.